The Joplin Globe

UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers

UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology ...
Enid News & Eagle

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and androgen deprivation therapy ...
The Eagle-Tribune

YARAL Pharma Launches 15-Count Diclofenac Epolamine Topical System 1.3%, Offering Pharmacists a Flexible, Space-Saving Option

YARAL Pharma Launches 15-Count Diclofenac Epolamine Topical System 1.3%, Offering Pharmacists a Flexible, Space-Saving Option ...
The Huntsville Item

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data ...
Standard-Journal

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial ...

Levi & Korsinsky, LLP announces that a securities class action has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX).
The Joplin Globe

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an ...
The Huntsville Item

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...
The Eagle-Tribune

Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting

Today, the Company presented results from a Phase 2b dose-ranging and proof of concept study of elismetrep, a novel TRPM8 ...
The Bakersfield Californian

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential ...
News-Press NOW

Uqora® Launches Cutting-Edge Urinary Health Products at Target

Uqora, the rapidly growing and cutting-edge urinary tract health brand, today announces its retail expansion into Target ...

'Our beating heart won't change': The history and future of Burnetts

How family law firm Burnetts developed over 100 years into one of the biggest in the north - and achieved B Corp status.
Barron's

Universal Music Group N.V.

About Universal Music Group N.V. Universal Music Group NV engages in the music entertainment business. The firm identifies and develops artists, and produces and distributes music. It operates through ...